In January 2024, the Dutch National Health Care Institute (Zorginstituut Nederland) published a comprehensive update to its Guideline for Economic Evaluations in Healthcare, the first since 2016. More than just a procedural refresh, this …

The reimbursement of orphan medicinal products (OMPs) for rare diseases remains one of the most complex challenges in European healthcare policy. These therapies frequently launch with limited clinical evidence, small target populations and high …

The UK is entering a bold new chapter in how innovative medicines and diagnostics reach patients, and it’s one that could re-define the global standard. With a series of strategic reforms unveiled …

How do we measure How healthy’ someone really is?  And how do we turn that into numbers that help shape health policy, pricing decisions and even drug approvals? That’s where the EQ-5D-5L comes in. Created …

In a landmark ruling, a US District Court has struck down the FDA’s attempt to regulate laboratory-developed tests (LDTs), a move celebrated by many in the scientific and diagnostics community, including the College of American …

On 25 March 2025, France’s Ministry of Labor, Health, Solidarity, and Families released key updates for the 2025 healthcare pricing campaign, marking significant developments for hospitals and clinics nationwide. The National Health Insurance Expenditure …

In a landmark move for women’s health, French health authorities have approved national reimbursement for theZiwig Endotest, a revolutionary saliva-based diagnostic for endometriosis. This non-invasive, mRNA-driven test now enters the public healthcare system under …

The National Institute for Health and Care Excellence (NICE) has recently updated the routing criteria for itsHighly Specialised Technologies (HST) appraisal process. These amendments, approved on 19 March 2025, will be implemented from 1 …